AIDS-related Kidney Disease

Phase II clinical trial of KRX-101 begins

Published in AIDS Weekly, April 8th, 2002

Keryx Biopharmaceuticals, Inc., (KERX) announced that it has begun initial dosing of patients in the phase II clinical trial of Keryx's investigational drug candidate KRX-101 (sulodexide) for the treatment of human immunodeficiency virus associated nephropathy (HIVAN) in AIDS patients. Keryx expects to have results of this clinical trial, which is being conducted in South Africa, within this calendar year.

"The initiation of this phase II trial and the initial dosing of patients is a significant milestone for us," said Dr. Benjamin Corn, Keryx Biopharmaceuticals' president and CEO. "We feel this is an important step in Keryx's ongoing efforts to provide an effective...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2002-04-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry

Search our medical news database